New FDA Rules Require More Minorities in Clinical Trials
By Radiant HealthPublished: April 17, 2022
The FDA will now require companies to file a “race and ethnic diversity plan” with the agency when working on clinical development for treatments. The new regulations for pharmaceutical and medical device companies will increase the number of Black individuals as well as other underrepresented minorities in their clinical trials. People from disadvantaged populations and diverse backgrounds are often left out because of factors like religious affiliation, illiteracy, a lack of knowledge about clinical trials, and a suspicion of medical professionals. The FDA’s Office of Minority Health and Health Equity will help companies to meet the new guidelines.
Like what you're reading? Sign up for our free newsletter and never miss a post! Plus get a FREE digital version of our Issue No.10 with sign up.
- 11 Best Health and Wellness Books to Read in 2024 - July 4, 2024
- Some Americans Will Have Medical Debt Wiped From Credit - July 9, 2022
- Natural Gas Used to Heat Homes Contains Some Harmful Chemicals - July 9, 2022
- Uterine Cancer Claims Many Black Lives - July 9, 2022
- Babies and Toddlers Get COVID-19 Shots - June 27, 2022
- FDA Bans Juul’s E-Cigarettes and Cartridges - June 27, 2022
- Polio Virus Found in London Sewage - June 27, 2022
- 200 Million Americans Are Drinking Contaminated Water - June 19, 2022
- Young Kids Can Finally Get Vaccinated Against COVID-19 - June 19, 2022
- New Regulations for Baby Sleep Products - June 19, 2022